Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

Market Cap	15.48B +137.2%
Revenue (ttm)	774.47M +27.9%
Net Income	56.52M +42.4%
EPS	0.14 +42.6%
Shares Out	405.71M
PE Ratio	273.51
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,313,216
Open	37.60
Previous Close	38.16
Day's Range	34.38 - 37.60
52-Week Range	17.34 - 44.90
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About SHA:688319

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b products. The company was founded in 2009 and is based in Chengdu, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 451
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688319

Financial Performance

In 2025, SHA:688319's revenue was 704.16 million, an increase of 19.58% compared to the previous year's 588.86 million. Earnings were 22.26 million, an increase of 7.24%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 16, 2026

Data Sources Report a data error